Global Patient Derived Xenograft (PDX) Models Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Patient Derived Xenograft (PDX) Models Market Segmentation, By Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Breast Cancer, and Others), Application (Preclinical Drug Development, and Oncology Research, Biomarker Analysis), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies)- Industry Trends and Forecast to 2032

Patient Derived Xenograft (PDX) Market Size

• The global patient derived xenograft (PDX) market size was valued at USD 228.11 million  in 2024 and is expected to reach USD 801.55 million  by 2032, at a CAGR of 17.01% during the forecast period
• This growth is driven by factors such as the rising demand for personalized cancer treatment, increasing prevalence of various cancer types, and the growing adoption of PDX models in preclinical and translational cancer research

Patient Derived Xenograft (PDX) Market Analysis

• Patient Derived Xenograft (PDX) models are highly accurate preclinical tools used in oncology research, offering a reliable platform for evaluating drug responses by implanting human tumor tissues into immunodeficient mice. They are essential for developing personalized cancer therapies and enhancing translational cancer research
• The demand for PDX models is significantly driven by the rising incidence of cancer globally, increasing focus on precision medicine, and the growing need for more predictive preclinical models in oncology drug development
• North America is expected to dominate the patient derived xenograft (PDX) market with largest market share of 45.1%, due to its robust biomedical research infrastructure, strong presence of leading pharmaceutical and biotechnology companies, and high investment in cancer research and development
• Asia-Pacific is expected to be the fastest growing region in the PDX market during the forecast period, fueled by increasing cancer prevalence, expanding clinical research capabilities, and rising healthcare expenditure in countries such as China, India, and Japan
• Breast cancer segment is expected to dominate the market with a largest market share of 32.2% due to increasing cases of breast cancer globally. Increasing prevalence of cancer cases would lead to significant investment in breast cancer research and drug development, driving demand for more reliable preclinical models such as PDX models. Thus, as the need for new therapies grows, particularly for metastatic and drug-resistant forms of breast cancer, the demand for PDX models will also grow significantly to study tumor biology and test novel treatment strategies

Report Scope and Patient Derived Xenograft (PDX) Market Segmentation    

Patient Derived Xenograft (PDX) Market Trends

“Rising Integration of PDX Models in Precision Oncology and Drug Screening”

• One prominent trend in the global Patient Derived Xenograft (PDX) market is the growing integration of PDX models into precision oncology and personalized drug screening platforms
• These models offer high fidelity in replicating human tumor heterogeneity and microenvironments, enabling more accurate assessment of treatment responses and biomarker identification 

  • For instance, pharmaceutical companies are increasingly using PDX platforms to screen targeted therapies and immuno-oncology drugs, improving clinical trial success rates and accelerating time-to-market for novel treatments 

• This trend is significantly transforming preclinical cancer research by enhancing the predictive power of drug testing, supporting personalized treatment strategies, and driving demand for PDX-based solutions across academic and commercial R&D settings

Patient Derived Xenograft (PDX) Market Dynamics

Driver

“Growing Cancer Burden Driving Demand for Predictive Preclinical Models”

• The rising global incidence of various cancers, including breast, lung, colorectal, and pancreatic cancers, is significantly contributing to the increased demand for patient derived xenograft (PDX) models in oncology research and drug development
• As cancer cases continue to surge, particularly due to aging populations, lifestyle factors, and environmental exposures, there is a growing need for more accurate and patient-representative models to guide treatment strategies and therapeutic innovations
• PDX models offer higher translational relevance than traditional in vitro or cell line models, helping researchers better understand tumor behavior, drug resistance, and treatment response in real-world scenarios

For instance,

• According to the World Health Organization’s 2022 report, cancer was responsible for nearly 10 million deaths in 2020, with projections indicating a steady rise in global cancer incidence over the next decade. This rising burden intensifies the need for advanced tools like PDX models to support targeted drug development and personalized oncology 
• As a result, the growing cancer burden is acting as a key driver for the global PDX market, encouraging pharmaceutical companies and research institutions to adopt these models for improved efficacy and safety evaluation of anti-cancer therapies

Opportunity

“Integration of Artificial Intelligence and Data Analytics in PDX Research”

• The integration of artificial intelligence (AI) and advanced data analytics into PDX research is emerging as a transformative opportunity, enabling faster and more accurate insights from complex biological datasets
• AI algorithms can be used to analyze genomic, transcriptomic, and phenotypic data from PDX models, helping researchers predict drug responses, identify potential biomarkers, and streamline the development of personalized therapies
• Machine learning techniques can enhance model selection, optimize study design, and reduce the time and cost associated with preclinical trials by offering predictive simulations of drug efficacy and toxicity

For instance,

• Recent AI-driven platforms, such as those developed by pharmaceutical AI companies, are being employed to analyze large-scale PDX datasets to uncover actionable targets and refine patient stratification strategies for oncology trials 
• This opportunity not only improves the predictive accuracy and efficiency of drug discovery but also opens doors for the broader adoption of PDX models in precision medicine, ultimately advancing cancer treatment outcomes

Restraint/Challenge

“High Cost and Ethical Concerns Hindering PDX Model Adoption”

• The high cost of developing and maintaining patient derived xenograft (PDX) models presents a significant challenge for the market, especially for small to mid-sized research institutions and pharmaceutical companies with limited R&D budgets
• Establishing and sustaining PDX models involves complex procedures, long development timelines, and substantial investment in specialized facilities and immunodeficient animals, all of which contribute to elevated operational costs
• Ethical concerns surrounding the use of animal models, especially in regions with stringent animal welfare regulations, can further impede the widespread adoption of PDX technology in certain markets

For instance,

• A 2023 review published in Frontiers in Oncology highlighted that the average cost of generating and maintaining a single PDX model can range from USD 5,000 to over USD 15,000, depending on tumor type and experimental design, limiting scalability in resource-constrained settings 
• Consequently, these financial and ethical barriers can restrict broader implementation of PDX models, particularly in low- and middle-income countries, slowing down progress in translational cancer research and personalized therapy development

Patient Derived Xenograft (PDX) Market Scope

The market is segmented on the basis of type, tumor type, application, and end user

In 2025, the breast cancer is projected to dominate the market with a largest share in tumor type segment

The breast cancer segment is expected to dominate the patient derived xenograft (PDX) market with the largest share of 32.2% due to increasing cases of breast cancer globally. Increasing prevalence of cancer cases would lead to significant investment in breast cancer research and drug development, driving demand for more reliable preclinical models such as PDX models. Thus, as the need for new therapies grows, particularly for metastatic and drug-resistant forms of breast cancer, the demand for PDX models will also grow significantly to study tumor biology and test novel treatment strategies

The mice models is expected to account for the largest share during the forecast period in type segment

In 2025, the mice models segment is expected to dominate the market with the largest market share due to their well-established immunodeficient strains, cost-effectiveness, and ease of handling. These models provide a reliable and reproducible platform for studying human tumor growth, metastasis, and response to therapies. In addition, the availability of genetically modified mice, such as those with specific mutations or immune deficiencies, enables the creation of more precise models that better reflect human cancer biology

Patient Derived Xenograft (PDX) Market Regional Analysis

“North America Holds the Largest Share in the Patient Derived Xenograft (PDX) Market”

• North America dominates the global Patient Derived Xenograft (PDX) market with largest market share of 45.1%, due to its advanced healthcare infrastructure, strong research capabilities, and the presence of key market players
• The U.S. holds a significant share of approximately 39.4%, due to increased demand for personalized medicine, advancements in cancer research, and robust funding for research and development in the biotechnology sector
• The well-established regulatory framework, along with a large number of pharmaceutical and biotech companies conducting preclinical trials, further strengthens the market position in this region

“Asia-Pacific is Projected to Register the Highest CAGR in the Patient Derived Xenograft (PDX) Market”

• The Asia-Pacific region is expected to witness the highest growth rate in the Patient Derived Xenograft (PDX) market, driven by rapid improvements in healthcare infrastructure and growing investments in the biotechnology sector
• Countries such as China, India, and Japan are emerging as key markets due to their increasing focus on cancer research and the growing demand for preclinical cancer models
• Japan, with its advanced medical technology and increasing number of research institutes, remains a crucial market for PDX models, while China and India benefit from large patient populations and increased adoption of clinical research

Patient Derived Xenograft (PDX) Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Crown Bioscience Inc. (US)
• THE JACKSON LABORATORY (US)
• Champions Oncology, Inc. (US)
• Charles River Laboratories (US)
• Wuxi AppTec (China)
• Oncodesign (Canada)
• Aragen Bioscience (India)
• Biocytogen (US)
• Bioduro (US)
• Creative Animodel (US)
• Covance Inc. (US)
• EPO Berlin-Buch GmbH (Germany)
• EUROPDX. (Belgium)
• Explora BioLabs (US)
• Hera BioLabs (US)
• Horizon discovery Ltd. (UK)
• Pharmatest Services (Finland)
• Urospehere SAS (Cyprus)
• Xentech (France)
• Xenopat (France)

Latest Developments in Global Patient Derived Xenograft (PDX) Market

• In August 2024, Altogen Labs, a prominent preclinical contract research organization (CRO), announced the successful validation of a comprehensive set of 10 lung cancer xenograft models. These models are essential for evaluating the in vivo efficacy of novel therapeutics aimed at treating lung cancer, thereby advancing the understanding, diagnosis, and treatment of primary lung carcinoma. This development underscores the growing role of patient-derived xenograft (PDX) models in accelerating cancer research and therapeutic innovation, contributing to the expansion of the global PDX market, particularly in oncology drug development
• In May 2024, BioAtla, Inc., a clinical-stage biotechnology company, announced receiving FDA authorization for its innovative antibody-drug conjugate (ADC) BA3361, designed to target multiple tumor types. The company demonstrated the superior efficacy of BA3361 in both cell line-derived xenograft models and patient-derived xenograft (PDX) models, including pancreatic cancer, showcasing complete tumor regression and reduced toxicity owing to CAB selectivity. This advancement highlights the growing importance of PDX models in the development of targeted cancer therapies, further driving the demand for PDX models within the global oncology research and therapeutic landscape
• In March 2024, Crown Bioscience, a leading global contract research organization (CRO), announced its plans to present groundbreaking research at the AACR 2024 meeting, featuring data derived from its Patient-Derived Xenograft (PDX) models. These PDX models are integral to advancing preclinical oncology research, facilitating the development of more targeted and personalized cancer therapies. This development underscores the increasing reliance on PDX models in oncology research, fueling the growth and adoption of PDX models in the global biotechnology and pharmaceutical sectors
• In December 2022, Crown Bioscience, Inc., a subsidiary of JSR Life Sciences, entered into a global licensing agreement with ERS Genomics Limited, granting the company comprehensive access to ERS's CRISPR/Cas9 patent portfolio. This agreement allows Crown Bioscience to leverage CRISPR/Cas9 technology for genetic editing on a global scale. This development highlights the growing significance of advanced genetic tools in enhancing the precision and effectiveness of patient-derived xenograft (PDX) models, which are crucial in the development of personalized cancer therapies and further propels the global PDX market's expansion
• In July 2022, GemPharmatech formed a strategic licensing partnership with Charles River Laboratories, Inc., granting the company exclusive distribution rights for GemPharmatech's advanced NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The availability of these specialized models further contributes to the growing demand for PDX-based studies, advancing the development of personalized cancer therapies and supporting the global PDX market

SKU-21255